Literature DB >> 6388925

Cell populations and membrane attack complex in glomeruli of patients with post-streptococcal glomerulonephritis: identification using monoclonal antibodies by indirect immunofluorescence.

G Parra, J L Platt, R J Falk, B Rodriguez-Iturbe, A F Michael.   

Abstract

Poststreptococcal glomerulonephritis (PSGN) had been thought to arise from renal deposition of immune complexes and as such is analogous to acute serum sickness. Recent studies of acute serum sickness in animals and PSGN in humans, however, have suggested a pathogenetic role for cellular immunity. To enlarge on these observations, cellular components of glomeruli were characterized by indirect immunofluorescence in 11 tissues from individuals with PSGN using monoclonal antibodies. These studies demonstrate infiltration of glomeruli by monocytes, granulocytes, and lymphoid cells. Focal accumulations of T lymphocytes were also observed adjacent to Bowman's capsule. Analysis of glomerular T-cell subpopulations revealed a predominance of cells reactive with OKT4 early and with OKT8 later in the course of disease. Proliferation of parietal and visceral epithelial cells was associated with increased binding of BA-1 and J5, respectively. The presence of the membrane attack complex of complement was demonstrated by glomerular reactivity with a monoclonal antibody (poly-C9 MA) which recognizes a neoantigen present in poly-C9. Fluorescence was present along the glomerular basement membrane early and within the mesangium late in the course of disease, a distribution similar to that observed for C3 and C5. These observations suggest that immune cells as well as terminal components of complement either provoke or mark tissue injury in PSGN.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6388925     DOI: 10.1016/0090-1229(84)90303-9

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex.

Authors:  J Bariety; N Hinglais; S Bhakdi; C Mandet; M Rouchon; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  Immunohistochemical studies of reflux nephropathy. The role of extracellular matrix, membrane attack complex, and immune cells in glomerular sclerosis.

Authors:  K Yoshioka; T Takemura; K Matsubara; H Miyamoto; N Akano; S Maki
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

3.  Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells.

Authors:  S Adler; P J Baker; R J Johnson; R F Ochi; P Pritzl; W G Couser
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.

Authors:  F Niculescu; F Hugo; H G Rus; R Vlaicu; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

5.  Terminal complement complexes in acute poststreptococcal glomerulonephritis.

Authors:  D G Matsell; R J Wyatt; L W Gaber
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

6.  Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy.

Authors:  A V Cybulsky; H G Rennke; I D Feintzeig; D J Salant
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

7.  Characterization of a complement-binding protein, DRS, from strains of Streptococcus pyogenes containing the emm12 and emm55 genes.

Authors:  Michael Binks; K S Sriprakash
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 8.  Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Authors:  Jacob J E Koopman; Mieke F van Essen; Helmut G Rennke; Aiko P J de Vries; Cees van Kooten
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.